Article
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC).
Bioorganic & medicinal chemistry - 15 Jul 2024
Patil Bhatu R, Bhadane Kunal V, Ahmad Iqrar, Agrawal Yogesh J, Shimpi Amit A, Dhangar Mayur S, Patel Harun M
Abstract excerpt
The USFDA granted regular approval to Osimertinib (AZD9291) on March 2017, for treating individuals with metastatic Non-Small Cell Lung Cancer having EGFR T790M mutation. Clinically, Osimertinib stands at the forefront for the treatment of patients with Non-Small Cell Lung Cancer. Osimertinib forms a covalent bond with the Cys797 residue and predominantly spares binding to WT-EGFR, thereby reducing toxicity and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.